Vertex Pharma's non-opioid painkiller suzetrigine was unable to perform better than placebo in a phase 2 trial in lumbar ...

New Delhi: Rahi Sarnobat recalls that autumn day of 2022 with clarity. Indian shooters, following a medalless Tokyo Olympics ...

In a small clinical study, researchers in the US examined the nature of new-onset pain reported by people with long COVID and explored potential associations between long COVID symptoms and pain.

With a history of spinal injury and having not undergone a surgical stabilization, a syrinx was suspected. A magnetic resonance imaging (MRI) study of the patient's cervical and thoracic spine was ...

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) said it submitted an Investigational New Drug (IND) application to the FDA to start ...

Sangamo Therapeutics, Inc. has groundbreaking treatments for neuropathic pain and Hemophilia A. Click for my updated look at ...

Neuropathic osteoarthropathy, otherwise known as Charcot neuroarthropathy, is a chronic, degenerative arthropathy and is associated with decreased sensory innervation. Numerous causes of this ...

MIRA READ THE FULL MIRA RESEARCH REPORT MIRA Pharmaceuticals (NASDAQ:MIRA) is a preclinical-stage pharmaceutical company that is about to be a clinical-stage company focused on the development and com ...

The following is a summary of “Effects of multiple transcranial magnetic stimulation sessions on pain relief in patients with chronic neuropathic pain: A French cohort study in real-world clinical ...

MIRA Pharmaceuticals (MIRA), has submitted an Investigational New Drug application to the U.S. Food and Drug Administration for Ketamir-2, its ...

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage pharmaceutical company focused on developing therapies for neurological and neuropsychiatric disorders, today announced that it has ...

"We are sincerely grateful to the patients and physicians who participated in our Zynquista™ clinical trials, and the broader diabetes community who strongly advocated for Zynquista’s approval," said ...